Our First Investor Update
First Week In, Over 200% Funded
From all of us at InnaMed, thank you!
In the first week since the launch of our campaign on Republic.co/InnaMed, we have already raised over 200% of our goal.
- We are excited to announce our endorsement by the Wharton Impact Venture Associates (WIVA). WIVA is an organization at the Wharton School of Business that connects local Philadelphia startups that have the potential to positively impact society with Wharton Alumni that are interested in supporting them.
On May 1st, we began work on our contract with the Translational Research Institute for Space Health (TRISH). TRISH is a strategic partnership between NASA and a consortium of research universities. Here is what Emmanuel Urquieta, M.D., M.S., a scientist at TRISH, has to say about us: "InnaMed's robust, portable blood testing technology is highly suitable for use in patient homes as well as in space exploration where resources are limited. With InnaMed's novel low-cost hardware and DNA-based reagents, we are excited about the potential of this technology and look forward to this team's outcome in moving blood testing closer to the patient."
Dr. Dan Bensimhon, a cardiologist and co-director of the Heart Failure Clinic at Cone Health, has joined our team as an advisor. He is a strong proponent of our vision to bring blood testing to the home for heart failure patients and is our largest investor to date on the Republic platform. Thank you Dr. Bensimhon - your support as a key opinion leader means a lot to us and we look forward to working with you.
We love what we do, and we’re excited to build a company that will globally improve the cost, access and quality of healthcare.
Let's keep this momentum going.
- The InnaMed Team